TP53 (Ab-315) Antibody

What is the TP53 (Ab-315) Antibody and what epitope does it recognize?

TP53 (Ab-315) Antibody is a research tool designed to bind specifically to the p53 protein, a critical tumor suppressor encoded by the TP53 gene. This antibody targets epitopes in the central DNA-binding domain (DBD) of p53, which comprises the core functional region of the protein. The p53 protein consists of 393 amino acids organized into five domains: the N-terminal transactivation domain (TAD), proline-rich domain (PRD), central DNA-binding domain (DBD), tetramerization domain (TD), and C-terminal regulatory domain (CTD) . Antibodies targeting different epitopes within these domains serve various research applications, with those recognizing the DBD being particularly valuable for detecting both wild-type and many mutant forms of p53.

How does p53 function as a tumor suppressor?

P53 functions primarily as a transcription factor that regulates over 300 direct target genes and potentially thousands of indirect targets . Upon various stress signals (DNA damage, oncogene activation, ribosomal stress, telomere erosion, nutrient deprivation, or hypoxia), p53 rapidly assembles into a functional tetramer that recognizes specific binding sites in promoters or enhancers of target genes . This activates transcriptional programs that induce cell-cycle arrest, apoptosis, and senescence, which serve as critical barriers to prevent tumorigenesis . Additionally, p53 plays important roles in maintaining genome stability, regulating metabolism, and modulating immune responses, further contributing to its tumor suppressive functions.

What are the common TP53 mutations in cancer and how do they affect antibody detection?

The TP53 gene is the most commonly mutated cancer driver gene, with mutations present across numerous cancer types . The arginine-to-histidine substitution at codon 175 (R175H) represents the most frequent TP53 mutation and is the most common mutation in any tumor suppressor gene . Other hotspot mutations include R248Q, R273H, R282W, and G245S. These mutations typically occur in the DNA-binding domain, altering p53's ability to bind target DNA sequences and activate transcription.

When using antibodies for p53 detection, it's important to consider that:

• Most mutations lead to protein stabilization and accumulation, often making mutant p53 more readily detectable than wild-type p53

• Conformational mutations may alter epitope accessibility for certain antibodies

• Some antibodies are specifically designed to detect mutant forms (like the R175H mutation) while others recognize both wild-type and mutant p53

• Validation using positive and negative controls containing known p53 status is essential for accurate interpretation of results

What are the differences between polyclonal and monoclonal anti-p53 antibodies?

The choice between polyclonal and monoclonal antibodies depends on the specific research application. Polyclonal antibodies may be preferred for initial screening or applications requiring high sensitivity, while monoclonal antibodies offer greater consistency and specificity for standardized assays or when targeting specific p53 conformations or mutations.

What are the optimal protocols for using TP53 (Ab-315) Antibody in immunohistochemistry?

For optimal immunohistochemistry (IHC) results with TP53 antibodies, researchers should follow these methodological guidelines:

• Tissue preparation:

  • Use fresh tissues fixed in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin following standard protocols

  • Cut sections at 3-5 μm thickness

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Pressure cooking for 10-15 minutes or microwave heating for 20 minutes

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

  • Apply protein block (serum-free) for 20 minutes

  • Dilute TP53 (Ab-315) Antibody to optimal concentration (typically 1:100-1:500, but optimization is essential)

  • Incubate overnight at 4°C or for 1-2 hours at room temperature

• Detection and visualization:

  • Use polymer-based detection systems for enhanced sensitivity

  • Develop with DAB substrate for 5-10 minutes

  • Counterstain with hematoxylin for nuclear visualization

• Controls:

  • Include positive controls (tissues known to express p53, particularly mutant p53)

  • Include negative controls (p53-null tissues or primary antibody omission)

  • Consider using cell lines with known p53 status as additional controls

Interpretation should consider that wild-type p53 typically shows weak, focal staining while mutant p53 often demonstrates strong, diffuse nuclear positivity due to protein accumulation.

How can I optimize Western blot protocols for detecting p53 using antibodies?

For optimal Western blot detection of p53:

• Sample preparation:

  • Extract proteins using RIPA buffer supplemented with protease inhibitors

  • Include phosphatase inhibitors if studying phosphorylated forms of p53

  • Sonicate briefly to shear DNA and reduce sample viscosity

  • Quantify protein concentration using Bradford or BCA assay

• Gel electrophoresis and transfer:

  • Load 20-50 μg of total protein per lane

  • Use 10-12% SDS-PAGE gels for optimal p53 (53 kDa) resolution

  • Transfer to PVDF membrane at 100V for 60-90 minutes or 30V overnight at 4°C

• Antibody incubation:

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Dilute TP53 (Ab-315) Antibody to manufacturer's recommended concentration (typically 1:1000)

  • Incubate overnight at 4°C with gentle agitation

  • Wash thoroughly with TBST (3-5 times, 5-10 minutes each)

  • Incubate with appropriate HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour

• Detection:

  • Use enhanced chemiluminescence (ECL) detection

  • For low expression levels, consider using more sensitive ECL substrates

  • Exposure time should be optimized based on signal intensity

• Controls and normalization:

  • Include positive controls (cell lines with known p53 expression)

  • Use appropriate loading controls (β-actin, GAPDH, or total protein staining)

  • Consider using p53-null cells as negative controls

When interpreting results, remember that wild-type p53 is often present at low levels due to rapid turnover, while mutant p53 typically shows higher expression due to increased stability.

What are the considerations for using anti-p53 antibodies in immunoprecipitation studies?

Immunoprecipitation (IP) with anti-p53 antibodies requires careful attention to several factors:

• Lysis conditions:

  • Use non-denaturing lysis buffers to preserve protein-protein interactions

  • Common buffers include NP-40 or CHAPS-based buffers with protease inhibitors

  • Include phosphatase inhibitors when studying p53 phosphorylation

  • For studying p53-DNA interactions, consider cross-linking before lysis

• Antibody selection:

  • Choose antibodies validated for IP applications

  • Consider the epitope location and accessibility in native conditions

  • Conformation-specific antibodies may be useful for specific research questions

• IP procedure:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Use 2-5 μg antibody per 500 μg-1 mg of total protein

  • Incubate antibody with lysate overnight at 4°C with gentle rotation

  • Add protein A/G beads and incubate for 1-4 hours

  • Wash thoroughly (at least 3-5 times) with lysis buffer

• Elution and analysis:

  • Elute bound proteins by boiling in SDS sample buffer

  • For gentler elution (to preserve interactions), consider elution with excess epitope peptide

  • Analyze precipitated proteins by Western blot or mass spectrometry

• Critical controls:

  • Include isotype-matched control antibody IP

  • Use p53-null cells as negative controls

  • Consider including MDM2 inhibitors (e.g., Nutlin-3) to stabilize wild-type p53 for enhanced detection

When investigating p53 interactome, remember that interactions may be influenced by stress conditions, post-translational modifications, and mutational status of p53.

How can anti-p53 antibodies be utilized in developing therapeutic approaches for p53-mutant cancers?

The development of therapeutic approaches targeting mutant p53 using antibodies has shown promising potential:

• Bispecific antibody approaches:
  Hsiue et al. developed a bispecific antibody targeting the neoantigen derived from the p53 R175H mutation . This approach:

  • Identified a peptide fragment (HMTEVVRHC) from mutant p53 that binds to HLA-A*02:01

  • Created an antibody (H2) that specifically recognizes this peptide-HLA complex

  • Converted H2 into a bispecific antibody by fusing it with an anti-CD3 antibody fragment

  • This bispecific antibody redirected T cells to kill cancer cells expressing the mutant p53 peptide-HLA complex

  • Demonstrated efficacy in xenograft models despite low antigen density

• Key considerations for antibody-based therapies:

  • Intracellular location of p53 necessitates targeting of peptide fragments presented on HLA

  • Specificity for mutant but not wild-type p53 is crucial to avoid toxicity

  • Antibody affinity must be high enough to recognize low-density antigens

  • The therapeutic format must efficiently activate immune effector functions

• Potential for personalized immunotherapy:

  • Different p53 mutations generate distinct neoantigens

  • Patient HLA type determines which peptides can be presented

  • Antibody-based approaches could be tailored to specific mutation/HLA combinations

  • This approach could potentially address the "undruggable" nature of mutant tumor suppressor genes

This therapeutic strategy represents a paradigm shift from trying to restore wild-type p53 function to instead exploiting the mutant protein as a cancer-specific antigen for immune targeting.

What is the significance of circulating anti-p53 antibodies in cancer patients?

Circulating anti-p53 antibodies (p53-Abs) are found in the sera of cancer patients and have important research and clinical implications:

Researchers investigating circulating anti-p53 antibodies should consider combining their measurement with other biomarkers for improved clinical utility.

How do post-translational modifications of p53 affect antibody recognition and experimental design?

Post-translational modifications (PTMs) of p53 significantly impact antibody recognition and must be carefully considered in experimental design:

• Major p53 PTMs affecting antibody recognition:

  • Phosphorylation: Multiple serine/threonine sites (S15, T18, S20, S46) are phosphorylated upon stress

  • Acetylation: Several lysine residues in the DBD and CTD undergo acetylation

  • Ubiquitination: Regulates p53 stability and localization

  • Methylation, SUMOylation, and neddylation: Affect p53 function and stability

• Epitope masking effects:

  • PTMs can mask antibody epitopes by altering protein conformation

  • Modifications near the antibody recognition site may sterically hinder binding

  • Some PTMs create new epitopes recognized by specific modification-sensitive antibodies

• Experimental considerations:

  • Use phospho-specific antibodies to detect activation-related modifications

  • Include phosphatase inhibitors when studying phosphorylated p53

  • Consider deacetylase inhibitors when studying acetylated forms

  • Use proteasome inhibitors to prevent degradation of ubiquitinated p53

• Modification-specific antibody applications:

  Modification	Key Sites	Biological Significance	Antibody Application
  Phosphorylation	S15, T18, S20	DNA damage response, MDM2 inhibition	Monitoring stress activation
  Phosphorylation	S46	Apoptosis induction	Assessing cell fate decisions
  Acetylation	K120, K164	Activation of apoptotic genes	Studying transcriptional specificity
  Acetylation	K382	General transcriptional activation	Monitoring p53 activation
  Ubiquitination	Multiple lysines	Proteasomal degradation	Studying p53 stability

• Technical solutions:

  • Use multiple antibodies recognizing different epitopes to confirm results

  • Include appropriate controls with known modification status

  • Consider protein extraction methods that preserve modifications of interest

  • Validate antibody specificity using modification-mimicking or preventing mutations

Understanding the complex interplay between p53 PTMs and antibody recognition is essential for accurate interpretation of experimental results, particularly in stress response and cancer research contexts.

How should researchers interpret p53 immunostaining patterns in tumor samples?

Interpreting p53 immunostaining requires understanding the relationship between staining patterns and p53 functional status:

When interpreting p53 immunostaining, consider that the relationship between staining pattern and mutational status varies by tumor type and may require validation in specific cancer contexts.

What are the best practices for validating the specificity of anti-p53 antibodies?

Rigorous validation of anti-p53 antibodies is essential for reliable research results:

• Cell line validation:

  • Test antibodies on p53 wild-type, mutant, and null cell lines

  • Use isogenic cell lines differing only in p53 status when possible

  • Include cell lines with common p53 mutations (R175H, R248Q, R273H)

  • Validate using multiple techniques (Western blot, IHC, IF, flow cytometry)

• Genetic validation approaches:

  • siRNA or shRNA knockdown of p53 in wild-type cells

  • CRISPR-Cas9 knockout of p53 as negative controls

  • Ectopic expression of wild-type or mutant p53 in p53-null cells

  • Use of inducible p53 expression systems to confirm specificity

• Epitope mapping and cross-reactivity testing:

  • Determine the exact epitope recognized using peptide arrays or deletion constructs

  • Test cross-reactivity with p53 family members (p63, p73)

  • Evaluate specificity across species if applicable to research aims

  • Assess recognition of post-translationally modified forms

• Reproducibility assessment:

  • Test multiple antibody lots to assess batch-to-batch variation

  • Compare results with other validated antibodies targeting different p53 epitopes

  • Document validation results thoroughly for publication and reproducibility

• Common validation pitfalls to avoid:

  • Relying solely on manufacturer's validation data

  • Using inappropriate positive or negative controls

  • Failure to account for p53 isoforms or post-translational modifications

  • Overlooking potential cross-reactivity with related proteins

Thorough validation not only ensures reliable results but also helps in selecting the most appropriate antibody for specific applications and experimental conditions.

How can researchers correlate p53 antibody-based detection with genomic and transcriptomic data?

Integrating p53 antibody-based detection with genomic and transcriptomic data provides comprehensive insights into p53 biology:

By integrating these diverse data types, researchers can gain deeper insights into the relationship between p53 genotype, expression, and function in both research and clinical contexts.

How are anti-p53 antibodies being utilized in the study of p53 isoforms and their functions?

The p53 protein exists in multiple isoforms with distinct functions, presenting both challenges and opportunities for antibody-based research:

• Overview of p53 isoforms:

  • Full-length p53 (FLp53) comprises 393 amino acids organized into five domains

  • At least 12 different p53 isoforms arise from alternative splicing, alternative promoter usage, and alternative translation initiation

  • Major isoforms include Δ40p53, Δ133p53, Δ160p53, and various C-terminal variants (α, β, γ)

  • These isoforms have distinct functions in development, aging, and cancer

• Antibody selection strategies:

  • N-terminal-specific antibodies: Detect full-length but not Δ40p53, Δ133p53, or Δ160p53

  • Central domain antibodies: May detect most isoforms depending on specific epitope

  • C-terminal antibodies: Distinguish between α, β, and γ variants

  • Isoform-specific antibodies: Target unique junctions created by alternative splicing

• Research applications:

  • Mapping isoform expression patterns across tissues and developmental stages

  • Determining isoform-specific interactomes through co-immunoprecipitation

  • Investigating differential subcellular localization of isoforms

  • Assessing isoform-specific functions in cell fate decisions and stress responses

• Methodological considerations:

  • Use multiple antibodies targeting different domains for comprehensive detection

  • Validate specificity using isoform-specific expression constructs

  • Consider Western blotting with appropriate resolving gels to separate isoforms

  • Employ RNA interference targeting specific isoforms as controls

• Emerging research directions:

  • Development of isoform-specific monoclonal antibodies

  • Investigation of isoform-specific post-translational modifications

  • Analysis of isoform ratio changes during tumorigenesis and therapy response

  • Examination of isoform-specific transcriptional programs

Understanding the complex interplay between p53 isoforms is critical for deciphering the multifaceted roles of p53 in normal physiology and disease states.

What role do anti-p53 antibodies play in studying p53's involvement in metabolism and ferroptosis?

Recent research has revealed expanding roles for p53 beyond its classical functions, particularly in metabolism and ferroptosis, where antibodies serve as critical research tools:

• p53's metabolic functions:

  • Regulates glycolysis, oxidative phosphorylation, and glutaminolysis

  • Modulates lipid metabolism and synthesis

  • Controls reactive oxygen species (ROS) levels

  • Influences nutrient sensing and mTOR signaling

• p53's role in ferroptosis:

  • Ferroptosis is an iron-dependent form of regulated cell death characterized by lipid peroxidation

  • p53 can promote ferroptosis through transcriptional regulation of genes involved in iron metabolism and antioxidant defense

  • p53 acetylation at specific lysine residues in the DNA-binding domain is critical for its ability to activate targets responsible for ferroptosis

• Antibody applications in metabolism research:

  • Tracking p53 subcellular localization in response to metabolic stress

  • Chromatin immunoprecipitation to identify metabolic gene targets

  • Co-immunoprecipitation to study p53 interactions with metabolic enzymes

  • Western blotting to examine stress-specific post-translational modifications

• Antibody applications in ferroptosis research:

  • Detecting acetylated p53 forms specifically involved in ferroptosis regulation

  • Immunoprecipitation of p53 complexes involved in ferroptotic pathways

  • Immunofluorescence to visualize p53 in cellular compartments during ferroptosis

  • Flow cytometry to correlate p53 status with ferroptotic markers

• Experimental design considerations:

  • Include appropriate metabolic inhibitors or inducers to study p53 responses

  • Use ferroptosis inducers (erastin, RSL3) and inhibitors (ferrostatin-1, liproxstatin-1)

  • Consider nutrient availability and culture conditions that affect metabolic state

  • Account for the impact of cell density and oxygen levels on metabolic phenotypes

This expanding understanding of p53's role in metabolism and ferroptosis opens new avenues for therapeutic approaches targeting these pathways in p53-mutant cancers.

How can anti-p53 antibodies contribute to the study of p53's role in the immune response to cancer?

The intersection of p53 biology and cancer immunology represents an exciting frontier where antibodies serve as valuable research tools:

• p53's immunological functions:

  • Regulates expression of immune checkpoint molecules

  • Influences cytokine and chemokine production

  • Affects antigen presentation machinery

  • Modulates tumor microenvironment composition

• Antibody applications in p53-immune research:

  • Multiplex immunohistochemistry to correlate p53 status with immune infiltration

  • Chromatin immunoprecipitation to identify p53 binding at immunoregulatory genes

  • Co-culture experiments to assess how p53 status affects immune cell interactions

  • Flow cytometry to correlate p53 expression with immune checkpoint molecules

• Therapeutic antibody development:

  • Bispecific antibodies targeting p53 neoantigens: As demonstrated by Hsiue et al., bispecific antibodies can redirect T cells to kill cancer cells expressing mutant p53 peptide-HLA complexes

  • This approach exploits the immune system to target cancer cells based on their presented p53 mutant peptides

  • Such bispecific antibodies can induce regression of human xenograft tumors in mice

• Key research considerations:

  • HLA type significantly affects which p53 mutant peptides can be presented

  • The density of peptide-HLA complexes on cell surfaces may be very low, requiring highly sensitive detection methods

  • Different p53 mutations generate distinct neoantigens with varying immunogenicity

  • Tumor microenvironment can modulate the presentation and recognition of p53 epitopes

• Emerging directions:

  • Development of antibodies to detect p53 neoantigen presentation on cancer cells

  • Investigation of how p53 status affects response to immune checkpoint inhibitors

  • Analysis of p53-mediated regulation of antigen processing and presentation machinery

  • Engineering of antibody-based therapeutics targeting p53-related neoantigens

This research area holds particular promise for developing novel immunotherapeutic approaches for cancers harboring p53 mutations, which represent a substantial proportion of human malignancies.